From standard gene monomer feedstocks to intricate mini-nucleic acids and mRNAs, CD Formulation provides outstanding quality and value to our customers. We provide our customers with a comprehensive one-stop solution for nucleic acid drug formulation, encompassing a full range of services from sequence design and synthesis to optimization and delivery systems.
Nucleic acid drugs are therapeutics that regulate gene expression at the post-transcriptional and pre-translational stages, acting upstream of protein synthesis. Compared to traditional small molecule drugs and antibody therapies, nucleic acid drugs offer several advantages, including ease of design, shorter development cycles, high target specificity, broad therapeutic applications, and prolonged efficacy.
Fig.1 Aptamer-based DDSs. (Tan X, et al., 2020)
Types of Nucleic acid drugs
CD Formulation offers comprehensive solutions for nucleic acid formulations, focusing on delivering end-to-end services from project design to production. We ensure the efficiency, safety, and stability of nucleic acid drugs while providing robust technical support for both research and industrialization. By partnering with us, you can significantly expedite the development and commercialization of nucleic acid drugs.
Fig.2 Solutions for nucleic acid formulations. (CD Formulation)
Nucleic acid design encompasses the creation and optimization of nucleic acid sequences from the ground up to enhance their potency and specificity. This process includes designing oligonucleotide sequences that bind selectively to the target RNA or DNA, predicting secondary structures, and minimizing the formation of unintended secondary structures and potential off-target effects.
Based on the advanced nucleic acid synthesis platforms we provide, we can guarantee high purity, high yield, and superior quality of nucleic acid products. The synthesized nucleic acids undergo a rigorous purification process, which includes high-performance liquid chromatography (HPLC) and mass spectrometry analysis, to ensure the purity and consistency of the final products.
Nucleic acid optimization involves the modification and transformation of initially synthesized oligonucleotides to enhance their stability, biological activity, and in vivo safety. Common optimization techniques include chemical modifications of nucleotides (e.g., phosphate bond modification, sugar ring modification), nucleic acid lock modifications, and 2'-O-methyl modifications, among others.
According to the characteristics of the drug, appropriate delivery carriers (e.g., lipid nanoparticles, polymer nanoparticles, viral vectors, etc.) are selected. These systems can protect nucleic acid molecules, enhance their stability in vivo, and facilitate their entry into target cells by traversing cell membranes. Additionally, advanced delivery systems enable targeted delivery, which increases the accumulation of nucleic acid drugs in specific tissues or cells through the modification of specific targeting molecules.
According to the characteristics of the drug, appropriate formulation types (e.g., liquid formulations, lyophilized powder injections, etc.) are developed to enhance the stability, solubility, and bioavailability of the drug. The preparation process necessitates the strict implementation of a quality control system to ensure the safety, consistency, and efficacy of the formulation.
Our core technologies for nucleic acid drugs encompass sequence design, synthesis, formulation development, and delivery technologies.
Technology: Lipid nanoparticles (LNPs) as drug delivery platforms for nucleic acids
Journal: ACS nano
IF: 15.8
Published: 2021
Results:
Lipid nanoparticles (LNPs) have emerged as a promising carrier in the pharmaceutical industry for a wide range of therapeutic applications.The ability of LNPs to encapsulate therapeutic drugs and deliver them to specific locations in the body, as well as release their contents at the desired time, provides a valuable platform for the treatment of a wide range of diseases. The authors identify emerging trends such as nanostructured lipid carriers and solid lipid nanoparticles that are becoming the platform of choice for numerous formulations. Recent advances in LNP formulations as drug delivery platforms, such as antitumor and nucleic acid therapies and vaccine delivery systems, are discussed.
Fig.3 LNP formulations as drug delivery platforms. (Tenchov R, et al., 2021)
Relying on our robust technology platform and professional team, CD Formulation is dedicated to providing customers with efficient and reliable nucleic acid drug formulation solutions. We focus not only on precise operations and high-quality standards at every stage of the process but also place special emphasis on the critical steps of process validation and scale-up production to ensure the safety and efficacy of our products. Contact us to help advance your nucleic acid drug development and production.
References